technology

Capsid engineering

Directed evolution and rational design of viral capsid proteins to alter tissue tropism, evade pre-existing neutralising antibodies and improve manufacturing yield.

Where it's used

In-vivo gene therapy: AAV and lentiviral vectors
One-time, potentially curative genetic medicines delivered by engineered adeno-associated and lentiviral vectors — eight FDA-approved in-vivo products since 2017, from Luxturna to Beqvez, now a multi-billion-dollar clinical reality alongside honest commercial retrenchments.
therapeutics-platforms 7 min